Access innovative COPD treatments while advancing medical research by participating in our new clinical trial evaluating a potential add-on treatment option.
Those who qualify and choose to participate may be compensated up to $1,800 for up to 18 in-clinic visits and 23 remote visits over approximately 1-3 years.
This study is looking at whether an investigational medication called depemokimab can help reduce future flare-ups in people with chronic obstructive pulmonary disease, or COPD in adults aged 40-75. The aim is to understand how well this medication works and how safe it is when added to a person’s usual COPD treatment.
Depemokimab has already been tested in previous clinical studies to understand its safety. This study builds on that knowledge by following people with COPD over a longer period of time.
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 50% chance you will receive the study treatment and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like depemokimab but does not contain any active ingredient. Everyone in the study will continue their regular COPD inhaler treatments throughout the study. Rescue medication will also be provided.
You will be on this study for approximately 1-3 years, depending on when you enter the study, which will include a screening period, a run-in period, a treatment period, and a follow-up period. The study will require up to 18 in-clinic visits and 23 remote visits. If you qualify and choose to participate, you may be compensated up to $1,800 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.
Those who qualify and choose to participate could receive:
Access to the study
treatment at no cost
Access to our top-tier team of board-certified study physicians at no cost
Compensation up to $1,800 for up to 18 in-clinic visits and 23 remote visits over approximately 1-3 years
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be reviewed by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.